Wearable Injectors Market Size, Share & Trends Analysis Report By Type (On-body, Off-body), By Technology (Spring-based, Motor-driven), By Application (Oncology, Autoimmune Diseases), By End Use, And Segment Forecasts, 2021 - 2028

Report Overview

The global wearable injectors market size was valued at USD 4.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 17.2% from 2021 to 2028. The rising prevalence of chronic diseases, such as cancer, cardiovascular disease, and diabetes, is expected to boost market growth during the forecast period. Another factor driving the market is the increasing number of biologics in the drug development pipeline, which are difficult to deliver by a syringe. In most cases, biologics are injected by intravenous infusion in the hospital. However, over the past decade, self-administration in a home setting has become a growing trend. BD’s Libertas is currently being used for the administration of various biologic drugs under research, thereby capturing a market share in even the CRO industry. Cost and complexities associated with the traditional settings have urged patients to switch towards more cost-effective alternatives, creating demand for wearable injectors. Moreover, wearable injectors offer advantages such as ease of administration, reduced pain, and minimized hassle compared to syringes, thereby adding to market growth.

Chronically ill patients including children and elderly people are prone to use medications incorrectly. Lack of patient adherence to the prescribed medication treatment compromises patient safety and soars costs to both patients and healthcare systems. Research studies have shown that non-adherence to medications can account for about 50% of treatment failures, 125,000 deaths, and up to 25% of hospitalizations each year in the U.S. In such cases, wearable injectors manufacturers are expected to play a key role to develop patient-centric devices.

The risk of getting exposed to COVID-19 has urged patients, especially those suffering from chronic diseases, to opt for self-administration of medication at home. Healthcare providers are also keeping healthcare resources free for acute care or for COVID-19 infected patients. This has created the demand for remote care technologies, such as wearable injectors. Thus, amid the COVID-19 pandemic, the market for wearable injectors is expected to witness steady and positive growth during this period.

Type Insights

The on-body segment dominated the market in 2020 with a share of 55.7% and is projected to maintain its lead over the forecast period. These are comfortable to wear on the skin, particularly the stomach. They are also water-resistant and convenient to use at home.

In 2019, Enable Injections formed a partnership with Sanofi for its enFuse drug delivery platform. enFuse is an on-body drug delivery platform that has a self-contained drug transfer system, which is compatible with standard syringes or vial container formats. Based on type, the market is segmented into on-body and off-body wearable injectors.

The off-body segment is expected to witness the fastest growth over the forecast period as these devices eliminate perils, such as painful removal of devices, adhesive fitting issues to the skin, and skin sensitivity or irritation. Moreover, the increasing investment in remote device development is another factor expected to introduce numerous new products for the off-body segment.

Technology Insights

The spring-based segment dominated the market in 2020 with a share of 36.3% and is projected to maintain its lead over the forecast period. This is attributed to the rising demand for adhesive patches as these devices are user-friendly and enable patients to accurately deliver the drug subcutaneously by pressing one or more buttons on the device. Based on technology, the market is segmented into spring-based, motor-driven, rotary pump, expanding battery, and others, which include pressurized gas and collapsible reservoir technology-based wearable injectors.

The motor-driven segment is expected to register the highest CAGR during the forecast period due to increasing customer demand for these devices as they are more convenient for use as compared to others. Ypsomed AG offers YpsoDose, a large volume patch injector that is based on the motor-driven system. In 2020, the company collaborated with SCHOTT and Lonza to develop a comprehensive solution for wearable patch injectors for the subcutaneous self-administration of large volumes of liquid formulations.

Application Insights

The oncology segment dominated the market in 2020 with a share of 29.9% owing to the rising prevalence of cancer, coupled with an increasing shift toward self-administration of medication among patients. Based on application, the market is segmented into oncology, infectious diseases, cardiovascular diseases, autoimmune diseases, and others, which include anxiety, neurology, anemia/blood disorders, respiratory disorders, skin diseases, genetic disorders, and digestive disorders.

The autoimmune diseases segment is expected to be the fastest-growing segment over the forecast period due to the rising prevalence of diabetes and the increasing adoption of wearable injectors due to their competitive advantage over insulin pumps. Stevanato Group offers a wearable device, SG EZ-be Pod, for diabetes patients. In 2020, the company had planned investments of USD 482.02 million, of which a significant amount is allocated to R&D programs for the manufacturing of drug delivery systems, including SG EZ-be Pod, its wearable device for the treatment of diabetes.

End-use Insights

The home care segment dominated the market in 2020 with a share of 40.8% and is expected to maintain its lead over the forecast period. This is due to the rising preference for self-administration of medication and the increasing need to curb healthcare costs. In addition, the growing demand for technologically developed drug delivery, which lowers the hospitalization rate and requires minimal expertise, is expected to boost the market growth. Based on end-use, the market is segmented into hospitals, clinics, home care, and others.

The hospitals segment is expected to witness lucrative growth during the forecast period owing to the increased number of patients that require hospitalization. Moreover, the increasing number of hospitals across the globe is anticipated to drive the segment.

Regional Insights

North America dominated the market in 2020 with a share of 41.5% owing to the rising prevalence of chronic and lifestyle-related diseases and the presence of sophisticated healthcare infrastructure. In addition, the local presence of major market players in the U.S., such as Becton; Dickinson and Company; Johnson & Johnson Services, Inc.; Unilife Corporation; SteadyMed Therapeutics, Inc.; Amgen, Inc.; and Enable Injections, is expected to boost the market growth.

Asia Pacific is projected to be the fastest-growing regional market over the forecast period. This can be attributed to the increasing geriatric population, especially in countries such as Japan, a wide diabetic population in countries such as China, and the rise in the number of chronic diseases in this region. In November 2020, Terumo Corporation, a Japan-based medical technology company, received CE Mark for its MEDISAFE WITH insulin pump system. The product that is developed and manufactured in Japan is the first and only tubing-free patch pump for insulin delivery available in the country since its commercial launch in 2018. By obtaining CE Mark, the company will now be able to initiate the global product launch of its product.

Key Companies & Market Share Insights

Key players focus on growth strategies, such as new product launches, collaborations, partnerships, operational expansion, mergers & acquisitions, and patient awareness campaigns. For instance, in 2020, Sorrel Medical, a firm engaged in the manufacturing of wearable drug devices, opened a new manufacturing facility in Israel to scale up the production of wearable drug delivery devices.

Companies are closely monitoring the COVID-19 situation across the world. Becton, Dickinson and Company, one of the largest global medical technology companies, has ensured its manufacturing and distribution centers remain operational at the global level by continuing to enforce pandemic protocols across its facilities. The company’s pre-fillable syringe has become a technology key to the global COVID-19 vaccine rollout. This has urged the company to invest USD 1.2 billion to expand this business. A major highlight of the investment was that the extra cash was utilized by the company to fuel the development of advanced drug delivery products as well, including its Libertas wearable injector, which had completed a 50-subject human clinical trial in February 2020.

In June 2020, Insulet Corporation, a global leader in tubeless insulin pump technology with its Omnipod Insulin Management System, expanded its financial assistance program for its customers in the U.S., who were negatively impacted by the COVID-19 pandemic. Under the program, the customer may receive up to a six-month supply of products (60 Pods) free of charge. Customers who have lost the jobs and insurance as a result of the pandemic, and are not covered by Medicaid or other insurance, were covered under the program. Some prominent players in the global wearable injectors market include:

• Becton, Dickinson and Company

• Johnson & Johnson Services, Inc.

• F. Hoffmann-La Roche Ltd.

• Unilife Corporation

• SteadyMed Therapeutics, Inc.

• Amgen, Inc.

• Insulet Corporation

• Enable Injections

• West Pharmaceutical Services, Inc.

• CeQur SA

Wearable Injectors Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global wearable injectors market report on the basis of type, technology, application, end-use, and region:

• Type Outlook (Revenue, USD Million, 2016 - 2028)

  • On-body

  • Off-body

• Technology Outlook (Revenue, USD Million, 2016 - 2028)

  • Spring-based

  • Motor-driven

  • Rotary Pump

  • Expanding Battery

  • Other

• Application Outlook (Revenue, USD Million, 2016 - 2028)

  • Oncology

  • Infectious Diseases

  • Cardiovascular Diseases

  • Autoimmune Diseases

  • Others

• End-use Outlook (Revenue, USD Million, 2016 - 2028)

  • Hospitals

  • Clinics

  • Home Care

  • Others

• Regional Outlook (Revenue, USD Million, 2016 - 2028)

  • North America

  • U.S.

  • Canada

  • Europe

  • U.K.

  • Germany

  • France

  • Asia Pacific

  • Japan

  • China

  • Latin America

  • Brazil

  • Mexico

  • Middle East & Africa

  • South Africa